

Pierre-Régis Burgel, M.D., PhD

Date of birth: August 15th 1970

Université de Paris

Service de Pneumologie, Hôpital Cochin

Phone : 33 1 58 41 23 67

27 rue du Faubourg St Jacques

Fax : 33 1 46 33 82 53

75679 Paris Cedex 14, France

Email : pierre-regis.burgel@aphp.fr

RESPIRATORY SOCIETY MEMBERSHIPS

- **American Thoracic Society:** Membership # 00214669
- **European Respiratory Society:** Membership # 121992
- **European Cystic Fibrosis Society: Membership # 1241**
- **Société de Pneumologie de Langue Française**
- **Société Française de la Mucoviscidose**

EDUCATION AND RESEARCH

- **1989-1997:** Medical training. University of Paris. School of Medicine. Specialty: respiratory medicine.
- **1999:** MD (Respiratory Medicine). University of Paris. School of Medicine.
- **May 1999-October 2001: Post-Doctoral Fellowship:** Cardiovascular Research Institute, University of California San Francisco, Pr J.A. Nadel. Mechanisms of secretory cell differentiation in airway epithelium.
- **2002: Master of Science** in “Biology and physiology of the respiratory system”.
- **2006: PhD in Respiratory Cell Biology.** University of Paris-Medical School. (mentors: Pr J.A. Nadel, Pr D. Dusser). PhD thesis : Roles of EGF receptors and eosinophils in mucin production by nasal polyp epithelium.

CURRENT POSITION

- **Professor of Respiratory Medicine.** Université Paris Cité and Cochin Hospital-Assistance Publique Hôpitaux de Paris, Paris, France. # Conseil de l’Ordre des Médecins: 75/69500
- **Senior Consultant and Director:** Adult Cystic Fibrosis Centre, Cochin Hospital-Assistance Publique Hôpitaux de Paris, Paris, France.
- **Senior Researcher and Co-Principal Investigator:** INSERM U1016 (Cochin Institute, Paris, France): Acute and Chronic Airway Infection. Direction: 3 PhD thesis, 18 Master students.
- **National Coordinator:** French Rare Disease Network for Cystic Fibrosis (47 centers)
- **Principal Investigator:** ERN-LUNG cystic fibrosis center Cochin Hospital
- **Member of the Scientific Committee of the ECFS Patient Registry (2019-2022)**
- **President French Cystic Fibrosis Society: 2023-2027**

MAIN RESEARCH INTEREST

- COPD phenotypes (Co-leader of the INITIATIVES BPCO cohort)
- Cystic fibrosis (CF) in adults
- Chronic bacterial/fungal infection in COPD and CF

- Bronchiectasis (Member of EMBARC steering committee)

BIBLIOMETRICS

315 references on Pubmed

H index: 52 (Web of Science); 62 (Google Scholar)

REVIEWER AND EDITORIAL BOARD

- **Reviewer:** European Respiratory Journal, Thorax, American Journal Respiratory Critical Care Medicine, Chest, Scientific Report, Respiratory Research, Respiratory Medicine, Plos ONE, Canadian Medical Association Journal, Lancet Respiratory Medicine
- **Editorial board:** European Respiratory Journal; Journal of COPD
- **Associate Editor:** Journal of Cystic Fibrosis (since 2018); European Respiratory Journal (since 2022)
- **Chief Editor:** Respiratory Medicine and Research (2019-2023)

TASK FORCES

- ATS/ERS task force on COPD (2012-2013)
- ERS/ECFS task force on provision of care in adult with cystic fibrosis (2012-2014)
- ECFS/CFF task force on antimicrobial resistance in cystic fibrosis (2017-2019)
- ECFS task force on fungal infection in cystic fibrosis (2017-2018)

AWARDS

Mid Career GOLD medal in cystic fibrosis (European Respiratory Society, 2022)

Active GRANTS

- CIMENT study: Prevalence of non-tuberculous mycobacteria in France (300 k€; 2018-2021)
- Observational study of all patients under Orkambi in France (150 k€; 2017-2019)
- Observational cohort study of all patients under Kaftrio in France (800 k€ 2021-2024)
- Prognostic value of 6 min walk test in adults with CF (150 k€; 2016-2019)
- French-Canada collaboration: Registry studies, prognostic data (2019-2021; 30 k€)
- Fecal Immunologic Test in adults with CF (2018-2019; 30 k€)

Paris, March 24th, 2024